Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK.

British journal of clinical pharmacology - 1 Jul 2021

Youssef Essra, Kirkdale Charlotte L, Wright David J, Guchelaar Henk-Jan, Thornley Tracey

Abstract excerpt

AIMS: Pharmacogenetics (PGx) in the UK is currently implemented in secondary care for a small group of high-risk medicines. However, most prescribing takes place in primary care, with a large group of medicines influenced by commonly occurring genetic variations. The goal of this study is to quantitatively estimate the volumes of medicines impacted by implementation of a population-level, pre-emptive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pharmacogenetics
Share to Pharmacogenomic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Primary Health Care

Share to United Kingdom

Source

Identifiers

PMID: 33464647
DOI: 10.1111/bcp.14704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK.PMID 33464647Read ↗

Estimating the prevalence of potential and actionable drug-gene interactions in Irish primary care: a cross-sectional studySemantic proximity Read ↗

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The NetherlandsSemantic proximity Read ↗

Genotype-predicted drug response phenotypes and their co-occurrence with dispensed medicines among 738,531 participants in the UK Our Future Health studySemantic proximity Read ↗

Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General PractitionersSemantic proximity Read ↗

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.Semantic proximity Read ↗

Use of Pharmacogenetic Drugs by the Dutch PopulationSemantic proximity Read ↗

Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort studySemantic proximity Read ↗

Pre-emptive pharmacogenetic testing in the acute hospital setting: a cross-sectional studySemantic proximity Read ↗

[Pharmacogenetics in primary health care: implementation and future expectations].Semantic proximity Read ↗

Actionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population.Semantic proximity Read ↗

Pharmacogenomic alerts: developing guidance for use by healthcare professionalsSemantic proximity Read ↗

Evaluating genotype-treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.